Welcome to our dedicated page for Aldeyra Therapeutics SEC filings (Ticker: ALDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aldeyra Therapeutics SEC filings document a biotechnology issuer focused on investigational therapies for immune-mediated diseases and formal disclosures tied to its RASP modulator pipeline. Recent 8-K reports furnish press releases and corporate presentations covering reproxalap regulatory review, clinical and preclinical program updates, pipeline prioritization, and FDA-related disclosures for dry eye disease.
The filing record also covers governance and capital-structure matters, including definitive proxy materials for annual meeting proposals and director elections, board-transition disclosures, and the payoff and termination of the Hercules Credit Facility. These filings group Aldeyra's public-company record around operating updates, risk and forward-looking-statement disclosures, stockholder voting matters, and financing arrangements.
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report beneficial ownership of Aldeyra Therapeutics, Inc. common stock. They state beneficial ownership of 3,751,558 shares of common stock, representing 6.22% of the outstanding class.
Both entities report shared voting power over 3,381,606 shares and shared dispositive power over 3,751,558 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is described as a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
Aldeyra Therapeutics, Inc. executed an office lease with Bradford Street, L.L.C. for approximately 4,067 square feet at 23 Bradford Street, Concord, Massachusetts, to serve as its corporate headquarters.
The lease starts on September 1, 2026 and runs through September 30, 2029. It provides for an initial monthly base rent of $12,201.00, which increases annually, plus operating expenses, taxes, and other fees. Aldeyra will post a $50,000.00 security deposit.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Aldeyra Therapeutics, Inc. (ALDX) common stock. BlackRock reports beneficial ownership of 1,045,764 shares of common stock, representing 1.7% of the class. All of these shares are reported with sole voting power and sole dispositive power, with no shared voting or dispositive power.
The filing notes that the reported position reflects securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock and its subsidiaries and affiliates, excluding other disaggregated units. BlackRock also states that various persons have rights to dividends or sale proceeds related to these shares, but no such person holds more than five percent of Aldeyra’s outstanding common stock.
Aldeyra Therapeutics, Inc. reports ongoing regulatory interactions with the U.S. Food and Drug Administration related to reproxalap for the treatment of dry eye disease. On July 14, 2026, Aldeyra received minutes from an FDA Type A meeting held on June 10, 2026, which addressed potential resubmission of the New Drug Application for reproxalap.
On July 15, 2026, Aldeyra requested clarification of the FDA’s meeting minutes and intends to request a Type D meeting with the FDA to further discuss potential NDA resubmission. The Type D meeting is expected to be held by the end of the third quarter of 2026.
Director Nancy Miller-Rich received two stock option awards from Aldeyra Therapeutics, Inc. These options allow her to buy 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share, with an expiration date of June 8, 2036.
Each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date. Vesting is conditioned on her continued service on the Board of Directors and, for the larger grant, on the Compensation Committee through the applicable vesting date. These are compensation-related grants, not open-market purchases or sales.
Aldeyra Therapeutics director Douglas Richard received new stock option awards. The Form 4 shows three option grants to buy Common Stock at an exercise price of $1.72 per share, covering 2,323, 19,909, and 70,000 underlying shares, respectively.
Each grant becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided he continues serving in the specified roles: as a member of the Board, as Chairperson of the Board, and as a member of the Nominating/Corporate Governance Committee.
Aldeyra Therapeutics director Gary M. Phillips received three stock option grants. On the reported date, he was awarded options to buy 70,000, 6,636 and 4,977 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable on the one-year anniversary of the grant date, if he continues serving on the Board and its Compensation and Audit Committees as applicable.
Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation. One option for 2,323 shares of common stock and another for 70,000 shares were granted with an exercise price of $1.72 per share and an expiration date of June 8, 2036.
Each grant becomes exercisable for 100% of the underlying shares on the one-year anniversary of the grant date. Vesting is conditioned on Clark providing continuous service, respectively, as a member of the Board of Directors and of the Nominating/Corporate Governance Committee through the applicable vesting date.
Aldeyra Therapeutics director Neal Walker received two new stock option grants. On the grant date, he was awarded options for 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable one year after grant, contingent on his continued Board and Compensation Committee service.